Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsule
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Bladder (OAB)
Conditions
Overactive Bladder (OAB)
Trial Timeline
Oct 28, 2014 → Sep 7, 2016
NCT ID
NCT02294396About Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsule
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsule is a approved stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT02294396. Target conditions include Overactive Bladder (OAB).
What happened to similar drugs?
20 of 20 similar drugs in Overactive Bladder (OAB) were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02294396 | Approved | Completed |
Competing Products
20 competing products in Overactive Bladder (OAB)